Novel	JJ
pharmacological	JJ
approaches	NNS
to	TO
manage	VB
interstitial	JJ
lung	NN
fibrosis	NN
in	IN
the	DT
twenty-first	JJ
century	NN
.	.

Pharmacological	JJ
agents	NNS
currently	RB
in	IN
use	NN
to	TO
treat	VB
interstitial	JJ
lung	NN
fibrosis	NN
are	VBP
either	CC
ineffective	JJ
or	CC
too	RB
toxic	JJ
in	IN
humans	NNS
.	.

This	DT
review	NN
addresses	NNS
mechanistically	RB
based	VBN
novel	JJ
approaches	NNS
that	WDT
have	VBP
the	DT
potential	JJ
to	TO
minimize	VB
the	DT
accumulation	NN
of	IN
collagen	NN
in	IN
the	DT
lung	NN
,	,
a	DT
hallmark	NN
of	IN
lung	NN
fibrosis	NN
.	.

These	DT
approaches	NNS
include	VBP
maintaining	VBG
the	DT
intracellular	JJ
levels	NNS
of	IN
NAD	NNP
(	(
+	CC
)	)
and	CC
ATP	NN
,	,
blocking	VBG
the	DT
biological	JJ
activities	NNS
of	IN
TGF-beta	NN
and	CC
integrins	NNS
,	,
evaluating	VBG
the	DT
effectiveness	NN
of	IN
PAF-receptor	NN
antagonists	NNS
and	CC
NOS	NN
inhibitors	NNS
,	,
and	CC
developing	VBG
a	DT
new	JJ
generation	NN
of	IN
cysteine	NN
pro-drugs	NNS
with	IN
an	DT
adequate	JJ
degree	NN
of	IN
bioavailability	NN
.	.

A	DT
critical	JJ
analysis	NN
of	IN
each	DT
approach	NN
as	IN
it	PRP
relates	VBZ
to	TO
management	NN
of	IN
IPF	NN
in	IN
humans	NNS
is	VBZ
presented	VBN
.	.

